Ticagrelor and Peripheral Arterial Disease

Peripheral Arterial Disease Clinical Trial

Official title:

Impact of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin in Patients With Claudication and Peripheral Arterial Disease (PAD): Thrombus Burden Assessed by Optical Coherence Tomography

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02407314
• Other study ID #: ESR-14-10020
• Status: Terminated
• Phase: Phase 4
• Start date: June 2015
• Est. completion date: January 17, 2017

Study information

• Verified date: January 2019
• Source: Arkansas Heart Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an interventional study assessing the effectiveness of Ticagrelor on the reduction of thrombus burden using optical coherence tomography in patients undergoing peripheral artery stenting.

Description:

Prospective, randomized study, comparing ticagrelor + aspirin vs. aspirin monotherapy following the 4-week post-procedural combination of Ticagrelor or Plavix with low dose aspirin. The investigators will enroll a minimum of 40 patients. Patients will be enrolled if they have either claudication and/or critical limb ischemia, and angiographically identified superficial femoral artery (SFA) disease requiring intervention, with either total occlusion or a significant SFA stenosis with the presence of Optical Coherence Tomography (OCT) defined clot following stent placement.

Participants will be evaluated at baseline, 1 month, 4 months, 6 and 7 months following SFA intervention. At baseline demographic data will be collected, and anthropomorphic and physiological variables (body mass index, waist circumference, blood pressure). Baseline and 6-month ankle brachial index (ABI) will be performed. A 6-min walk test will be performed at baseline and 6-month follow-up. At 6 month time point patients in both treatment groups will return for a peripheral angiogram and repeat OCT imaging of the SFA segments of interest. Subject will have a final follow up clinic visit at 7 months.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 26
• Est. completion date: January 17, 2017
• Est. primary completion date: January 17, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with lower extremity claudication and PAD due to significant SFA stenosis (>60%) or total occlusions (Rutherford 2-6) that affects the quality of life despite medical therapy.

• The presence of OCT identified clot in the Superficial Femoral Artery (SFA) following stent placement.

• Evidence of significant SFA disease involving the most symptomatic limb established by noninvasive vascular testing (ankle-brachial index [ABI] <0.9, toe brachial Index [TBI] of <0.6. If ABI>1.4, SFA systolic acceleration time >140 milliseconds); computed tomographic angiography, or magnetic resonance angiography confirming at least a 60% stenosis of the SFA.

• At least one non-treated Below The Knee (BTK) vessel patent

• Male and female outpatients 18 years of age.

• The only following devices may be used for the revascularization procedures:

conventional balloons and bare metal stents (block randomization).

• Subject has been advised of the beneficial effects of smoking cessation and regular exercise but must not be in the process of changing their smoking status at the time of screening. Patients may resume or increase exercising as an effect of post procedurally improved lower limb perfusion.

• Peak Walking Time (PWT) limited only by claudication.

• Willingness to participate, documented by written informed consent.

Exclusion Criteria:

• Patients requiring dual anti-platelet drug treatment before start of study

• Planned amputation

• Use of atherectomy devices

• Hypersensitivity to acetylsalicylic acid, or ticagrelor. For ticagrelor, hypersensitivity reactions in the past include angioedema

• Patients with known bleeding disorders

• Patients with known active pathological bleeding

• Patients needing chronic oral anticoagulant maintenance therapy

• Patients with a history of intracranial hemorrhage at any time, GI bleed in the past 6 months, or major surgery within the past 30 days

• Ischemic stroke during the past 3 months

• Patients considered to be at risk of bradycardic events unless treated with a permanent pacemaker

• Target is a restenotic lesion or in-stent restenosis

• Any scheduled revascularization procedure requiring dual-anti-platelet therapy for more than one month

• Severe hypertension that may put the patient at risk, systolic greater than or equal to 180 and/or diastolic greater than or equal to 100

• Severe liver disease

• History of congestive heart failure with an Left Ventricular Ejection Fraction (LVEF) of less than 30%

• Concern for inability of the patient to comply with study procedures and/or follow up (eg, alcohol or drug abuse)

• Infra-popliteal disease involving the last remaining vessel (single run-off)

• Prior lower extremity revascularization within the past 30 days prior to enrollment

• Atherectomy of PAD

• EXCIPIENTS to ticagrelor hypersensitivity

• Known pregnancy, breast-feeding, or intend to become pregnant during the study period (all female patients 55 years and younger, without past history of hysterectomy must have a pregnancy test prior to peripheral intervention at baseline and at 6 months)

• Creatinine clearance < 30 mL/min

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Procedure:
• Percutaneous Peripheral Intervention
Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.

Device:
• Optical Coherence Tomography
This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. The device used is a cardiac catheter with OCT sensors on the tip of it. It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.

Other:
• Ankle Brachial Index
This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
• Six minute walk distance
Assessment of the walking distance in 6 minutes.

Drug:
• Aspirin
Aspirin, also known as acetylsalicylic acid [ASA], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
• Aspirin + Ticagrelor
This is a combination of drugs (Aspirin + Ticagrelor). Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor. Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.

Locations

Country	Name	City	State
United States	Arkansas Heart Hospital	Little Rock	Arkansas

Sponsors (3)

Lead Sponsor	Collaborator
Arkansas Heart Hospital	The University of Texas Health Science Center at San Antonio, University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the Intraluminal clot volume (in mm3)	Intraluminal clot volume will be assessed by Optical Coherence Tomography using a Core Lab.	At baseline and at 6 months
Primary	Change in the Intraluminal clot length (mm)	Intraluminal clotlength will be assessed by Optical Coherence Tomography using a Core Lab.	At baseline and at 6 months